博利康尼协同普米克治疗小儿毛细支气管炎临床疗效分析

Analysis of Clinical Efficacy of Boliconi in Collaboration with Pumick in the Treatment of Capillary Bronchitis in Children

目的探讨分析博利康尼协同普米克治疗小儿毛细支气管炎的临床疗效。方法选取2016年1月1日~2017年12月31日住院的小儿毛细支气管炎患者92例,将其随机分为对照组与研究组各46例,两组均进行综合性治疗,包括抗病毒、止咳等,对照组给予地塞米松磷酸钠静脉滴注,研究组采用博利康尼协同普米克雾化吸入,7 d后比较两组患者治疗效果。结果对照组治愈30例,好转16例,治愈率65.2%;研究组治愈42例,好转4例,治愈率91.3%。两组治愈率比较差异具有统计学意义(χ^2=5.800,P<0.05)。结论博利康尼协同普米克治疗小儿毛细支气管炎治愈率高,临床疗效肯定。

Objective To investigate and analyze the clinical efficacy of Boliconi′s treatment of capillary bronchitis in children in collaboration with Pumick. Methods Selected 92 cases of pediatric capillary bronchitis patients admitted to our department from January 1, 2016 to December 31, 2017, and randomly divided them into control groups and study groups of 46 cases each, both groups were subjected to comprehensive treatment, including antiviral, cough control, etc., the control group gave dexamethasone sodium phosphate intravenous drips, and the study group used Boliconinprip mesothesize patients with two results. Results 30 cases were cured in the control group, 16 cases were improved, and the cure rate was 65.2%, and the study group was 42 cases, 4 cases were improved, and the cure rate was 91.3%. The difference in the treatment rate of the two groups was statistically significant(χ^2=5.800,P<0.05). Conclusions Boliconi worked with Pumick to treat small children with high curing rate of capillary bronchitis, and the clinical efficacy was positive.